Ezrin assay method for the in vitro diagnosis of colorectal cancer

Abstract

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

1 . A monoclonal antibody directed against an epitope selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7, and SEQ ID No.8. 
     
     
         2 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.1. 
     
     
         3 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.2. 
     
     
         4 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.3. 
     
     
         5 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.4+SEQ ID No.5. 
     
     
         6 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.6+SEQ ID No.7. 
     
     
         7 . The monoclonal antibody of  claim 1  directed against the epitope of SEQ ID No.8. 
     
     
         8 . The monoclonal antibody of  claim 1  attached to a label capable of producing a detectable signal. 
     
     
         9 . The monoclonal antibody of  claim 1  attached to an imaging tracer capable of producing a detectable signal. 
     
     
         10 . The monoclonal antibody of  claim 1  attached to a solid support. 
     
     
         11 . An assay comprising:
 the monoclonal antibody of  claim 2  as a first monoclonal antibody; and   a second monoclonal antibody directed against an epitope selected from the group consisting of SEQ ID No.2, SEQ ID No.4+SEQ ID No.5, and SEQ ID No.6+SEQ ID No.7.   
     
     
         12 . The assay of  claim 11 , wherein the second monoclonal antibody is directed against the epitope of SEQ ID No.4+SEQ ID No.5. 
     
     
         13 . A kit comprising:
 the monoclonal antibody of  claim 2  as a first monoclonal antibody; and   a second monoclonal antibody directed against an epitope selected from the group consisting of SEQ ID No.2, SEQ ID No.4+SEQ ID No.5, and SEQ ID No.6+SEQ ID No.7.   
     
     
         14 . The kit of  claim 13 , wherein the second monoclonal antibody is directed against the epitope of SEQ ID No.4+SEQ ID No.5. 
     
     
         15 . A hybridoma capable of producing the monoclonal antibody of  claim 1 . 
     
     
         16 . A method of obtaining the monoclonal antibody of  claim 1 , comprising:
 culturing a hybridoma capable of producing the monoclonal antibody so as to produce the monoclonal antibody; and   obtaining the monoclonal antibody produced by the cultured hybridoma.   
     
     
         17 . The method of  claim 16 , further comprising:
 immunizing an animal with an antigen comprising at least one epitope selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7, and SEQ ID No.8;   obtaining an antibody-producing lymphocyte from the immunized animal; and   fusing the antibody-producing lymphocyte with a myeloma cell to produce the hybridoma.